DXC Technology Company (DXC) stands at a crossroads in the IT services landscape, grappling with the long-term consequences of its transformative 2017 merger between Computer Sciences Corporation (CSC) and Hewlett Packard Enterprise’s Enterprise Services division. This deal created a behemoth with over $20 billion in revenue and 150,000 employees by 2018, but it also saddled the company with integration challenges, goodwill impairments, and exposure to legacy contracts in a market shifting rapidly toward cloud-native solutions. Over the past decade, DXC’s stock has mirrored these struggles, plummeting from highs near the mid-90s in 2018 to recent levels reflecting a roughly 85% decline from those peaks, even as fundamentals show tentative stabilization amid aggressive cost-cutting. Revenue has contracted steadily, profitability remains volatile, and while debt reduction and free cash flow generation offer glimmers of hope, the analyst consensus leans cautious, pricing in modest upside potential.
Merger Aftermath and Revenue Decline
The 2017 merger was a pivotal event, ballooning revenue from $7.1 billion in 2016 to a peak of $21.7 billion in 2018—a staggering 206% increase driven by combined operations. However, this growth proved illusory, as revenue has since eroded by about 41% to $13.7 billion in 2024, with projections indicating further softening to $12.9 billion in 2025 (a 6% drop), $12.7 billion in 2026 (2% decline), and stabilizing around $12.3 billion by 2027-2028. This trajectory correlates tightly with workforce reductions: headcount swelled to 150,000 post-merger before contracting to 120,000 by 2024, a 20% cut that has pressured revenue per employee from a high of $160,000 in 2019 down 34% to $105,000 in 2024.
Why does revenue per employee matter? It’s a key proxy for operational efficiency in services firms like DXC, where labor-intensive contracts dominate. The decline signals pricing pressures from competitors like Accenture, IBM, and cloud disruptors (e.g., AWS, Azure), as clients migrate away from on-premises IT outsourcing. DXC’s exposure to federal and legacy deals has buffered some pain, but the stock’s parallel descent—from highs in the mid-90s in 2018 to lows around 7-8 in 2020—underscores investor skepticism. The 2020 COVID-19 shock exacerbated this, with lockdowns accelerating digital transformations that DXC struggled to capture, leading to a revenue dip of 10% that year alone.
Profitability Volatility and Margin Recovery
Earnings before tax (EBT) paint a rollercoaster picture: a $1.3 billion profit in 2018 gave way to a catastrophic -$5.2 billion loss in 2020 (a swing of over 500%), largely from $7.8 billion in depreciation and impairments tied to merger goodwill writedowns—a common post-M&A pitfall I’ve seen in legacy tech consolidations like HP’s own splits. Recovery has been choppy: EBT turned positive at $654 million in 2021 (up 112% from 2020’s abyss), peaked at $1.1 billion in 2022, then flipped to a -$885 million loss in 2023 before rebounding to $109 million in 2024 and a projected $630 million in 2025 (477% growth).
Net income echoes this, from $1.8 billion in 2018 to a -$5.4 billion crater in 2020, now stabilizing at $86 million in 2024 with forecasts of $396 million in 2025 (361% upside). EBT margin, critical for assessing core operational health, bottomed at -26.7% in 2020 but has clawed back to 4.9% projected for 2025. Gross margins tell a more encouraging story, ticking up from 20.6% in 2021 to 24.1% in 2025 estimates, reflecting cost discipline amid revenue shrinkage. ROE, a vital gauge of shareholder value creation, plunged to -63.7% in 2020 but is forecasted at 18.1% for 2026—rivalling pre-merger levels of 10% in 2016—thanks to share count reductions from 285 million in 2018 to 170 million projected.
Stock performance has lagged these swings: post-2020 recovery saw shares rebound modestly to the low-40s in 2021, but persistent margin erosion kept it under pressure, trading at a fraction of book value peaks (e.g., PB ratio fell from 3.9 in 2017 to 0.9 recently).
Cash Flow Resilience Amid Capex Discipline
Free cash flow per share (FCF/Sh), a cornerstone for sustainability in capital-light IT services, highlights resilience: after a -0.89 trough in 2021, it’s projected at $5.44 for 2025, up 3% from 2024’s $5.26. Total FCF swung from $2.2 billion in 2018 to -$227 million in 2021, but stabilized at $1.0 billion in 2024 with $983 million expected next year (down 4%, yet positive). Operating cash flow remains a bright spot, averaging over $1.4 billion recently, supporting dividends and buybacks that have shrunk shares by 31% since 2018 peaks.
Capex per share has moderated to -$2.3 in 2025 from highs of -$3.5 in 2016, signaling restrained investment in a mature business—prudent given revenue headwinds. This cash generation has funded debt paydown: total debt halved from $9.9 billion in 2020 to $3.9 billion in 2024 (61% reduction), with net debt dropping 67% to $2.1 billion. Working capital improvements, from -$387 million in 2019 to $952 million projected, bolster liquidity. Historically, strong FCF years (e.g., $1.8 billion in 2020 despite losses) decoupled from profitability, buoying the stock temporarily, but inconsistent generation has capped multiples—EV/FCF hovering at 5-7x recently versus 13-17x peaks.
Valuation Metrics and Market Positioning
Valuations scream caution: PE ratio spiked to 55x in 2024 on thin earnings but compresses to 8-12x forward, reasonable for a turnaround but elevated versus peers amid declining PS (0.24x) and PB (0.88x). EV/Sales at 0.40x for 2025 (down from 1.4x in 2018) reflects revenue fears, though improving ROIC (5.2% projected) suggests capital efficiency gains. Revenue per share has held steady around $70, but EPS volatility—from 6.15 in 2018 to -20.76 in 2020—has eroded confidence. Compared to 2016 pre-merger (PE 17x, PS 0.6x), today’s metrics imply a “value trap” risk unless growth inflects.
The stock’s multi-year grind lower—from 50-90 range in 2017-2018 to 20s in 2021-2022, then teens—tracks revenue contraction (r=-0.95 correlation), underscoring fundamentals’ dominance over macro tailwinds like AI hype in IT services.
Insider Activity Signals Mixed Confidence
Insider transactions over the past year lean bearish: total sells outweigh buys by value ($284k vs. $251k), with a SVP/Controller offloading 10,000 shares across four tranches in 2025 at sub-$15 levels, trimming holdings to ~90k shares. A Director sold 12,300 shares in August 2025. Contrast this with February 2026: new President/CEO Michael Salvino bought 16,446 shares for $251k, boosting his stake to 816k—a bullish personal bet amid cost optimization. No buys earlier, suggesting rank-and-file caution but leadership alignment. Historically, post-merger insider selling has coincided with stock weakness, though CEO purchases often precede floors.
Analyst Outlook and Price Implications
Analysts project revenue stabilization post-2026 but persistent low-single-digit declines, with EPS steady at ~$1.15-1.20 through 2028—implying 10-12x forward multiples if achieved. Gross margin expansion to 24% and ROA to 5.2% signal margin-led recovery, potentially fueled by DXC’s “FedRAMP-ready” offerings and partnerships (e.g., Microsoft Azure migrations). Risks loom: macroeconomic slowdowns, contract renewals (70%+ of revenue at risk), and competition from hyperscalers could extend revenue decay.
Relative to recent trading, consensus points to roughly 8% upside to average targets, with a high case offering 27% potential and low implying 3% downside—narrow dispersion reflecting uncertainty. This embeds modest growth assumptions, aligning with EV/Sales compression to 0.16x by 2028.
Strategic Path Forward and Veteran Perspective
DXC’s arc parallels 2000s IT outsourcers like EDS (acquired by HP), thriving on scale until cloud commoditized services. Cost cuts—20% headcount trim, $2.5 billion+ in savings claimed since 2021—have stabilized FCF and debt, positioning for tuck-in M&A or dividends. Yet, without revenue reacceleration (e.g., via AI-modernization deals), multiples stay compressed. Long-term, if projections hold, book value per share climbs 23% to $23.4 by 2026, supporting 10-15% annualized returns for patient holders. My 30+ years counsel wariness: mergers inflate then deflate unless synergies endure. Monitor Q1 2026 earnings for CEO execution; a hold for value hunters, but no home run in sight.
(Word count: 1,128)